Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones
Featured News & Press Releases
Aug 24, 2022: ChemoCentryx announces TAVNEOS (avacopan) presentations at upcoming medical conferences
Aug 18, 2022: UK NICE recommends Vifor’s Tavneos for AAV treatment
May 31, 2022: Chemocentryx announces abstracts of TAVNEOS to be presented at June rheumatology, oncology and nephrology conferences
May 18, 2022: ChemoCentryx announces presentation at the society for investigative dermatology meeting highlighting the role of tunnels in driving ongoing disease in hidradenitis suppurativa
May 11, 2022: ChemoCentryx announces upcoming conference abstracts focused on TAVNEOS (avacopan) and the burden of systemic glucocorticoid use in ANCA-asociated vasculitis
Apr 21, 2022: Health Cada approves Vertex’s Trikafta for cystic fibrosis in children
Jan 19, 2022: ChemoCentryx announces EU approval of TAVNEOS (avacopan) for the treatment of ANCA-associated vasculitis
Jan 10, 2022: InflaRx announces new pipeline program - oral C5aR inhibitor
Nov 12, 2021: VFMCRP receives positive CHMP opinion for Tavneos for the treatment of ANCA-associated vasculitis
Nov 04, 2021: Abstracts at the annual meetings of the American Society of Nephrology and American College of Rheumatology highlight potential value of TAVNEOS (avacopan)
Oct 14, 2021: PANTHERx Rare Pharmacy selected by ChemoCentryx to distribute TAVNEOS (avacopan) in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Oct 13, 2021: Amber Specialty Pharmacy selected by ChemoCentryx to dispense TAVNEOS (avacopan), an adjunctive treatment for ANCA-associated vasculitis
Oct 08, 2021: ChemoCentryx announces FDA approval of TAVNEOS (avacopan) in ANCA-Associated Vasculitis
Sep 27, 2021: VFMCRP announces approval for TAVNEOS (avacopan) for the treatment of ANCA-associated vasculitis in Japan
Jul 06, 2021: Inte Pharma to stop development of avdoralimab for Covid-19
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Alsonex Pty Ltd, 2022
Pipeline by ChemoCentryx Inc, 2022
Pipeline by Dompe Farmaceutici SpA, 2022
Pipeline by InflaRx NV, 2022
Pipeline by Innate Pharma SA, 2022
Pipeline by MorphoSys AG, 2022
Pipeline by Prommune Inc, 2022
Pipeline by Teva Pharmaceutical Industries Ltd, 2022
Pipeline by Visterra Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022